<!DOCTYPE html>
<html xmlns="https://www.w3.org/1999/xhtml">

<head>
    <script src="https://s0.2mdn.net/ads/studio/Enabler.js"></script>
    <meta name="ad.size" content="width=300,height=250">
    <meta name="format-detection" content="telephone=no">
    <meta http-equiv="Content-Type" content="text/html; charset=UTF-8" />
    <meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=no, maximum-scale=1.0">
    <title>832227R0_Branded_Animated_Banner_4_Efficacy_300x250_v2</title>
    <link rel="stylesheet" type="text/css" href="styles/stageStyles.css">
    <link href="https://fonts.googleapis.com/css?family=Open+Sans:400,600,700" rel="stylesheet">
    <script src="js/jquery-2.1.0.min.js"></script>
    <script src="js/jquery.cycle.all.js"></script>
    <script type="text/javascript" src="js/jquery.tinyscrollbar.js"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/waypoints/2.0.3/waypoints.min.js"></script>
    <script src="js/jquery.counterup.min.js"></script>
    <script type="text/javascript">
            
        var clickTag1 = "https://www.nucala.com";
        var clickTag2 = "https://us.gsk.com/";
        var clickTag3 = "https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL.PDF";
        var clickTag4 = "https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL.PDF#nameddest=PIL";
        var clickTag5 = "https://www.mothertobaby.org/asthma";
        var clickTag6 = "https://www.fda.gov/medwatch";
        var clickTag7 = "https://www.gsksource.com/pharma/content/gsk/source/us/en/brands/nucala/pi/efficacy.html";
      </script>
    
    <script type="text/javascript">
        $(document).ready(function () {
            $('#footer').tinyscrollbar({trackSize: 53});
        });
    </script>
</head>

<body>
        <div id="stage">
           
           <!--Statics Elements-->
            
            <a id="ctaClick" href="javascript:window.open(window.clickTag7); void(0)">
            <a href="javascript:window.open(window.clickTag1); void(0)">
            <div class="first clickTags" id="canvas_click"></div></a>
            <a href="javascript:window.open(window.clickTag2); void(0)"  id="sponsor"> Sponsored by GSK
            </a>
             
            <div class="first" id="statics">
                 
                <div class="first" id="footer">
                <div class="first" id="button"> 
                <a href="javascript:window.open(window.clickTag3); void(0)">
                <div style="width:50%">
                    <img id="button-l" src="assets/button-l.jpg"/>
                </div>
                </a> 
                <a href="javascript:window.open(window.clickTag4); void(0)">
                <div style="width:50%; text-align: center; position: absolute; left: 150px; display: inline;">
                    <img id="button-r" src="assets/button-r.jpg">
                </div>
                </a>
                </div> 
                <div class="scrollbar">
                    <div class="track">
                        <div class="thumb">
                            <div class="end"></div>      
                        </div>
                    </div>
                </div>
                <div class="viewport">
                    <div class="overview">
                    <strong><span style="font-weight:bold; font-size:10px; letter-spacing: 0.5px">IMPORTANT SAFETY INFORMATION</span></strong> <span style="float:right; color: #84bd00; font-size:6pt">SCROLL HERE <img id="green-arrow" src="assets/green-arrow.png"/></span><br/>
                    <p style="margin-top: 5px; margin-bottom: -6px; letter-spacing: 0.25pt;">
                    <strong>CONTRAINDICATIONS</strong></p>

                       <p>NUCALA should not be administered to patients with a history of hypersensitivity to mepolizumab or excipients in the formulation.</p>
                        <p>
                        <strong>WARNINGS AND PRECAUTIONS</strong>
                        </p>

                        <p>
                        <strong>Hypersensitivity Reactions</strong>
                        </p>
                        <p>
                        Hypersensitivity reactions (eg, anaphylaxis, angioedema, bronchospasm, hypotension, urticaria, rash) have occurred with NUCALA. These reactions generally occur within hours of administration but can have a delayed onset (ie, days). If a hypersensitivity reaction occurs, discontinue NUCALA.
                        </p>
                        <p>
                        <strong>Acute Asthma Symptoms or Deteriorating Disease</strong>
                        </p>
                        <p>
                        NUCALA should not be used to treat acute asthma symptoms, acute exacerbations, or acute bronchospasm.
                        </p>
                        <p>
                        <strong>Opportunistic Infections: Herpes Zoster</strong>
                        </p>
                        <p>
                        In controlled clinical trials, 2 serious adverse reactions of herpes<br>zoster occurred with NUCALA compared to none with placebo.<br>Consider vaccination if medically appropriate.
                        </p>

                        <p>
                        <strong>Reduction of Corticosteroid Dosage</strong>
                        </p>
                        <p>
                        Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of therapy with NUCALA. Decreases in corticosteroid doses, if appropriate, should be gradual and under the direct supervision of a physician. Reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.
                        </p>

                        <p>
                        <strong>Parasitic (Helminth) Infection</strong>
                        </p>
                        <p>
                        Treat patients with pre-existing helminth infections before initiating therapy with NUCALA. If patients become infected while receiving NUCALA and do not respond to anti-helminth treatment, discontinue NUCALA until infection resolves.
                        </p>

                        <p>
                        <strong>ADVERSE REACTIONS</strong>
                        </p>
                        <p>
                        The most common adverse reactions (≥3% and more common than placebo) reported in the first 24 weeks of 2 clinical trials with NUCALA (and placebo) were: headache, 19% (18%); injection site reaction, 8% (3%); back pain, 5% (4%); fatigue, 5% (4%); influenza, 3% (2%); urinary tract infection, 3% (2%); abdominal pain upper, 3% (2%); pruritus, 3% (2%); eczema, 3% (<1%); and muscle spasms, 3% (<1%).
                        </p>

                        <p>
                        Systemic Reactions, including Hypersensitivity Reactions: In 3 clinical trials, the percentages of subjects who experienced systemic (allergic and nonallergic) reactions were 3% for NUCALA and 5% for placebo. Manifestations included rash, flushing, pruritus, headache, and myalgia. A majority of the systemic reactions were experienced on the day of dosing.
                        </p>

                        <p>
                        Injection site reactions (eg, pain, erythema, swelling, itching, burning sensation) occurred in subjects treated with NUCALA. 
                        </p> 

                        <p>
                        <strong>USE IN SPECIFIC POPULATIONS</strong>
                         </p>
                        <p>
                            A pregnancy exposure registry monitors pregnancy outcomes in women exposed to NUCALA during pregnancy. To enroll call <span class="nowrap">1-877-311-8972</span> or visit <a href="javascript:window.open(window.clickTag5); void(0)" style="text-decoration: underline;">www.mothertobaby.org/asthma</a>.
                            </p>
                        <p>
                        The data on pregnancy exposures are insufficient to inform on drug-associated risk. Monoclonal antibodies, such as mepolizumab, are transported across the placenta in a linear fashion as the pregnancy progresses; therefore, potential effects on a fetus are likely to be greater during the second and third trimesters.
                        </p>
                        <p>
                            <strong>To report SUSPECTED ADVERSE REACTIONS, contact GSK at<br><span class="nowrap">1-888-825-5249</span> or FDA at <span class="nowrap">1-800-FDA-1088</span> or <a style="text-decoration: underline;" href="javascript:window.open(window.clickTag6); void(0)">www.fda.gov/medwatch.</a></strong>
                        </p>    

                        <p>Trademarks owned or licensed by GSK.</p>
                        <p>
                        &copy;2018&nbsp;GSK or licensor.<br/> 832227R0 April 2018
                        </p>                    
                       
                    </div>
                </div>
            </div>
               </div>
            
        
        <!--FRAMES-->
      <!--<a href="javascript:window.open(window.clickTag5); void(0)">  <div id="arrow"> <img src="assets/arrow.png"> </div></a>-->
        
        <!--FRAME 1-->
        <div class="container" id="frame1">
           
            <div class="red"></div>
            <img class="zibg12 retina-fit" id="bg12" src="assets/bg12.jpg"/>
             
            <div class="second" id="copycontainer1">
              
               
                <div id="copy11">
                    <div class="letras" id="let111">S</div>
                    <div class="letras" id="let112">E</div>
                    <div class="letras" id="let113">V</div>
                    <div class="letras" id="let114">E</div>
                    <div class="letras" id="let115">R</div>
                    <div class="letras" id="let116">E</div>
                </div> 
                <div id="copy12">
                    <div class="letras" id="let121">A</div>
                    <div class="letras" id="let122">S</div>
                    <div class="letras" id="let123">T</div>
                    <div class="letras" id="let124">H</div>
                    <div class="letras" id="let125">M</div>
                    <div class="letras" id="let126">A</div>
                </div>
                <div id="lineTop"></div>
                <div id="copy13">
                    <div class="letras" id="let131">U</div>
                    <div class="letras" id="let132">P</div>
                    <div class="letras" id="let133">D</div>
                    <div class="letras" id="let134">A</div>
                    <div class="letras" id="let135">T</div>
                    <div class="letras" id="let136">E</div>
                </div>
                <div id="lineButton"></div>
                
            </div>
            <div class="second" id="copycontainer2">
            <div id="copy14">
                    Data you need to know<br>
                    about choosing a<br>
                    <strong>TARGETED THERAPY</strong>
                </div>
                   
                    
        </div>
        </div>
        
        <!--FRAME 2-->
               
                <div class="second" id="copycontainer4">
                 
                   <div id="copy4"> 
                        See the strong foundation of<br>
                        evidence supporting <span class="colorado"><strong>NUCALA</strong></span>  for<br>
                        <strong>severe eosinophilic asthma</strong>
                   </div>
                </div>
         
            <!-- FRAME 3-->
        
        <div class="container" id="frame3">
            
            <img class="second retina-fit" id="logo2" src="assets/logo2.png"/>
            <img class="second retina-fit" id="vial" src="assets/vial.png" />
           
            <div class="second" id="copycontainer5">
               <div  id="copy5">
                NUCALA is indicated for the add-on maintenance<br>
                treatment of patients 12 years and older with<br>
                severe asthma with an eosinophilic phenotype.<br>
                NUCALA is not indicated for the relief of acute<br>
                bronchospasm or status asthmaticus.
               </div>
            </div> 
           
           <!-- FRAME 4-->
          
            <div class="second" id="copycontainer6">
        
               <div  id="copy6">
                    <strong>CONSIDER <span class="colorado">NUCALA</span></strong><br/>
                    The first anti-interleukin 5 (IL-5) for <br>
                    <strong>severe eosinophilic asthma</strong>
               </div>
               <div id="cta"></div>
            </div> 
            
</div>
     </div>       
                           
        <script src="https://cdnjs.cloudflare.com/ajax/libs/gsap/1.18.4/TweenMax.min.js"></script>
        <script src="js/functions.js"></script>
        <script type="text/javascript">
                       
            $('.counter').counterUp({
                time: 2000
            });
                   
        </script>

</body>

</html>